Treatment of infectious diseases
AssigneeChildren's Medical Center Corporation
InventorsAnne Goldfeld, Luke Jasenosky, Viraga Haridas, Shahin Ranjbar
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating or preventing a disease comprising administering a pharmaceutical composition comprising a therapeutically-effective amount of nitazoxanide to a subject having the disease, wherein the disease is causally linked to infection by one or more pathogens selected from the group consisting of members of the genus Ebolavirus, members of the genus Marburgvirus, members of the species dengue virus, human immunodeficiency viruses 1 and 2, and members of the species Mycobacterium tuberculosis.
Claims14
A method of increasing an anti-viral response in a cell, the method consisting essentially of contacting the cell with nitazoxanide, wherein the anti-viral response is an anti-viral stress response.
A method of measuring an anti-viral response in a patient who has been administered nitazoxanide as a first anti-viral therapeutic, the method comprising
- measuring an expression level of interferon-induced transmembrane (IFITM) protein, protein kinase R (PKR), retinoic acid-inducible gene 1 (RIG-I), and growth arrest or DNA damage-inducible protein (GADD34).
A method of measuring an anti-viral response following administration of nitazoxanide, the method comprising
- a. measuring a first expression level of interferon-induced transmembrane (IFITM) protein, protein kinase R (PKR), retinoic acid-inducible gene 1 (RIG-I), and growth arrest or DNA damage-inducible protein (GADD34) in a subject;
- b. administering nitazoxanide to the subject;
- c. measuring a second expression level of interferon-induced transmembrane (IFITM) protein, protein kinase R (PKR), retinoic acid-inducible gene 1 (RIG-I), and growth arrest or DNA damage-inducible protein (GADD34) in a subject.
A method of increasing an anti-viral response in a cell, the method consisting essentially of contacting the cell with nitazoxanide, wherein the anti-viral response comprises formation of stress granules and/or increase in cellular acidity.
A method of increasing an anti-viral stress response in a cell, the method consisting essentially of contacting a cell with nitazoxanide in vivo, thereby increasing an anti-viral stress response in the cell.
Dependencies are inferred from the claim text.